



VLCR Clinical Quality Indicators

No.	Numerator	Denominator	
Timeliness Indicators			
1	Number of patients where time from referral to date to diagnosis is ≤28 days.	Number of patients in registry with referral and diagnosis dates available.	
2	Number of patients where time from diagnosis to first treatment date is ≤14 days.	Number of patients in registry receiving anti-cancer treatment with diagnosis and treatment dates available.	
3	Number of patients with NSCLC where time from diagnosis to surgical resection is ≤14 days.	Total number of NSCLC patients undergoing surgical resection with diagnosis and resection dates available.	
4	Number of patients where time from referral date to first treatment date is ≤42 days.	Total number of patients undergoing any intent anti-cancer treatment with referral and first treatment dates available.	
Documer	ntation in medical records indicators		
5	Number of patients with documented screening for supportive care.	Number of patients in the registry.	
6	Number of patients with documented ECOG status.	Number of patients in registry.	
7	Number of patients with NSCLC and documented clinical (cTNM) staging.	Total number of NSCLC patients.	
8	Number of patients with documented MDM presentation.	Number of patients in registry.	
9	Number of patients with documented PET scan.	Number of NSCLC patients undergoing surgical resection.	
Stage concordance and tissue diagnosis indicator			
10	Number of NSCLC patients undergoing surgical resection where cTN agrees with pTN.	Total number of patients with NSCLC who have had a surgical resection with cTN and pTN available.	
11	Number of patients with confirmed tissue diagnosis.	Number of patients in the registry.	
Treatmen	t indicators		
12	Number of patients who have had a surgical resection.	Total number of NSCLC patients with clinical stage I-II.	
13	Number of patients with ≥5 lymph nodes identified in pathology report.	Number of NSCLC patients (clinical stage I-II) who have undergone a surgical resection.	
14	Number of patients who have had a surgical resection and died within ≤30 days of surgery.	Number of NSCLC patients who have undergone a surgical resection.	





15	Number of NSCLC patients with NSCLC who have had a surgical resection and died ≤90 days of surgery.	Number of NSCLC patients who have undergone a surgical resection.	
16	Number of patients receiving anti-cancer treatment (resection, radiotherapy, chemotherapy, immunotherapy, or targeted therapy).	Number of patients in the registry.	
17	Number of patients who have received SACT.	Number of patients with NSCLC stage IIIB, IIIC or IV who have ECOG (0-1).	
18	Number of patients who have had an adjuvant platinum-based chemotherapy.	Number of NSCLC patients (pathological stage II-III) who have undergone a surgical resection.	
19	Number of patients with lung cancer where time from the start date of SACT to death date is ≤30 days.	Number of patients receiving SACT.	
Palliative care indicator			
20	Number of patients who have had a palliative care referral ≤ 8 weeks of diagnosis.	Number of patients with lung cancer type NSCLC (stage IV) and palliative care referral date available.	
Molecular indicators			
21	Number of patients who have had EGFR testing.	Number of patients with NSCLC non- squamous (stage IV).	
22	Number of patients who have had ALK testing.	Number of patients with NSCLC non- squamous (stage IV).	
23	Number of patients who have had ROS1 testing.	Number of patients with NSCLC non- squamous (stage IV).	
24	Number of patients who have had PDL1 testing.	Number of patients with NSCLC stage IV.	